Literature DB >> 11088076

Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas.

W K de Roos1, J H de Wilt, M E van Der Kaaden, E R Manusama, M W de Vries, A Bout, T L ten Hagen, D Valerio, A M Eggermont.   

Abstract

OBJECTIVE: To evaluate the potential of isolated limb perfusion (ILP) for efficient and tumor-specific adenovirus-mediated gene transfer in sarcoma-bearing rats. SUMMARY BACKGROUND DATA: A major concern in adenovirus-mediated gene therapy in cancer is the transfer of genes to organs other than the tumor, especially organs with a rapid cell turnover. Adjustment of the vector delivery route might be an option creating tumor specificity in therapeutic gene expression.
METHODS: Rat hind limb sarcomas (5-10 mm) were transfected with recombinant adenoviruses. Intratumoral luciferase expression after ILP was compared with systemic administration, regional infusion, or intratumoral injection using a similar dose of adenoviruses carrying the luciferase marker gene. Localization studies using lacZ as a marker gene were performed to evaluate the intratumoral distribution of transfected cells after both ILP and intratumoral injection.
RESULTS: Intratumoral luciferase activity after ILP or intratumoral administration was significantly higher compared with regional infusion or systemic administration. After ILP, luciferase gene expression was minimal in extratumoral organs, whether outside or inside the isolated circuit. Localization studies demonstrated that transfection was confined to tumor cells lying along the needle track after intratumoral injection, whereas after ILP, lacZ expression was found in viable tumor cells and in the tumor-associated vasculature.
CONCLUSIONS: Using ILP, efficient and tumor-specific gene transfection can be achieved. The ILP technique might be useful for the delivery of recombinant adenoviruses carrying therapeutic gene constructs to enhance tumor control.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11088076      PMCID: PMC1421274          DOI: 10.1097/00000658-200012000-00010

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  31 in total

1.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.

Authors:  D Lienard; P Ewalenko; J J Delmotte; N Renard; F J Lejeune
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544

2.  Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.

Authors:  M F Gnant; A C Berger; J Huang; M Puhlmann; P C Wu; M J Merino; D L Bartlett; H R Alexander; S K Libutti
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

3.  Adenovirus-mediated interleukin 3 beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma in rats.

Authors:  J H de Wilt; A Bout; A M Eggermont; S T van Tiel; M W de Vries; T L ten Hagen; W K de Roos; D Valerio; M E van der Kaaden
Journal:  Hum Gene Ther       Date:  2001-03-20       Impact factor: 5.695

4.  Surfactant protein A-directed toxin gene kills lung cancer cells in vitro.

Authors:  M J Smith; M D Rousculp; K T Goldsmith; D T Curiel; R I Garver
Journal:  Hum Gene Ther       Date:  1994-01       Impact factor: 5.695

5.  Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo.

Authors:  J M DiMaio; B M Clary; D F Via; E Coveney; T N Pappas; H K Lyerly
Journal:  Surgery       Date:  1994-08       Impact factor: 3.982

6.  Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanoma.

Authors:  E G Nabel; Z Yang; D Muller; A E Chang; X Gao; L Huang; K J Cho; G J Nabel
Journal:  Hum Gene Ther       Date:  1994-09       Impact factor: 5.695

7.  In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.

Authors:  M A Kay; C N Landen; S R Rothenberg; L A Taylor; F Leland; S Wiehle; B Fang; D Bellinger; M Finegold; A R Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

8.  Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans.

Authors:  G J Nabel; E G Nabel; Z Y Yang; B A Fox; G E Plautz; X Gao; L Huang; S Shu; D Gordon; A E Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

9.  The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.

Authors:  R N Scott; D J Kerr; R Blackie; J Hughes; G Burnside; R M MacKie; D S Byrne; A J McKay
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

10.  Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.

Authors:  J M Klaase; B B Kroon; J H Beijnen; G W van Slooten; J A van Dongen
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

View more
  5 in total

Review 1.  Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?

Authors:  T Pencavel; R Seth; A Hayes; A Melcher; H Pandha; R Vile; K J Harrington
Journal:  Gene Ther       Date:  2010-05-06       Impact factor: 5.250

Review 2.  Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives.

Authors:  A M Eggermont; T L ten Hagen
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

3.  A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors.

Authors:  C R Logg; C K Tai; A Logg; W F Anderson; N Kasahara
Journal:  Hum Gene Ther       Date:  2001-05-20       Impact factor: 5.695

4.  Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody fragment to p21-Ras.

Authors:  B van Etten; T L M ten Hagen; M R de Vries; G Ambagtsheer; T Huet; A M M Eggermont
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

5.  Impaired neutralising antibody formation and high transduction efficacy after isolated hepatic perfusion with adenoviral vectors.

Authors:  B van Etten; A M M Eggermont; G Ambagtsheer; S T van Tiel; T L M ten Hagen
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.